Heberbiovac HB

Recombinant vaccine against Hepatitis B

- Heberbiovac HB is safe and immunogenic
- Heberbiovac HB, besides protecting against type B hepatitis and its sequelae, is a good ally for controlling type D hepatitis
- Heberbiovac HB production is carried out according to the requirements of the World Health Organization (WHO)

Composition
Heberbiovac HB contains a hepatitis B virus surface antigenic protein preparation (HBsAg). This protein is obtained by means of DNA recombinant procedures.

Indications
For the active immunization against the HBV infection and the prevention of its potential consequences, acute and chronic hepatitis, hepatic cirrhosis and primary hepatocarcinoma. Immunization against the hepatitis D virus.

Contraindications
It should not be administered to patients suffering from fever due to severe infections, neither to patients allergic to any of the components of the vaccine.

Effectiveness
According to different studies, more than 95% of infected mothers' newborn children vaccinated immediately after birth, are protected.

Precautions
It is not recommended to vaccinate pregnant women. It is not necessary to interrupt pregnancy in case of deliberate vaccination. In case of high risk or other special cases the doctor should assess the administration.

Adverse reactions
Several studies have demonstrated very low reactogenicity for the vaccine. Only slight local reactions, such as limited induration, erythema and slight pain in the injection region can appear in some cases. Systemic reactions such as fever, headache, nausea and weakness appear in very few cases.

Administration
It is recommended to inject the preparation deeply intramuscularly in the deltoid region - not in the gluteus - or in the antero-lateral face of the thigh in newborn children under 1 year old.

Posology
- Newborns, children and adults up to 35 years old:
  - 10 Ag/0.5 ml is recommended
- Adults older than 35 years:
  - 20 Ag/0.5 ml is recommended

Two vaccination schemes can be applied:
- Three doses separated by intervals of one month (0, 1, 2 months).
- Two doses separated by an interval of one month, followed by a third dose six months after the first one (0, 1, 6 months).
In immunodepressed patients a higher dose is required, normally twice the normal one (40 Ag/2 ml).

Storage
Heberbiovac HB keeps its immunogenic capacity if stored at 2 - 8 °C up to 36 months. When stored at 37 °C up to one month and at 45 °C during one week, it maintains power and quality, although these storage conditions are not recommended. Avoid freezing.

Presentation
- Boxes of 1, 10 or 25 vials of 10 Ag/1.5 ml
- Boxes of 1, 10 or 25 vials of 20 Ag/ml
- Boxes of 1, 10, or 25 vials of 100 Ag/5 ml
- Boxes of 1, 10 or 25 vials of 200 Ag/10 ml